Rhinology
Indirect Treatment Comparison of Biologics Approved for CRSwNP
In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Sietze Reitsma discusses about indirect comparison of biologics for CRSwNP, focusing on clinical outcomes like symptom relief and safety and also highlights dupilumab, omalizumab, and mepolizumab as effective and well-tolerated options.
MD, PhD
Sietze Reitsma
Related resources
Learning objectives
- To evaluate the clinical effectiveness and safety profiles of biologics such as dupilumab, omalizumab, and mepolizumab across key treatment domains in CRSwNP
Description
This video provides an overview of an indirect treatment comparison of biologics approved for CRSwNP, emphasizing the challenges in comparing Phase 3 trial data due to differences in patient populations. It discusses the use of network meta-analysis to evaluate the relative effectiveness and safety of biologics such as dupilumab, omalizumab, and mepolizumab across various clinical domains including symptom scores, quality of life, smell function, corticosteroid use, need for surgery, polyp size, and CT imaging.
Tags
MAT-GLB-2506247 - 1.0 - 10/2025
About this expert
Rhinology
Sietze Reitsma
MD, PhD
ENT and Rhinologist at the University Medical Centres in Amsterdam | Professor at the Department of Otorhinolaryngology and Head and Neck Surgery | University of Amsterdam
See author’s profile